Media coverage of medical devices, pharmaceuticals, and clinical therapies plays a crucial role in public health communication by raising awareness and encouraging dialogue between patients and healthcare providers. However, the line between objective reporting and promotion can easily blur. To clarify this distinction, Australia’s Therapeutic Goods Administration (TGA) issued guidance titled Determining when news is subject to the therapeutic goods advertising rules. This resource outlines legal obligations under the Therapeutic Goods Act 1989, Therapeutic Goods Regulations 1990, and Therapeutic Goods Advertising Code Instrument 2021 for journalists, publishers, broadcasters, and commercial sponsors.
Indicators of Unlawful Advertising in News Formats
Conversely, news content is regulated as advertising if it displays promotional characteristics, such as:
- Unbalanced claims using sensational language like "breakthrough" or "life-changing".
- Omitting risks.
- Incorporating testimonials that prompt consumers to seek specific treatments.
Regulatory Exemptions and Commercial Intent
Direct-to-consumer advertising of prescription medicines and biologicals remains strictly prohibited in Australia, while over-the-counter medicines and medical devices may be advertised only if compliant with the Advertising Code. Although Section 6 of the Code provides limited exemptions for certain print publishers and broadcasters who take reasonable steps to verify compliance, these exceptions do not apply universally. Practical examples from the TGA demonstrate that reporting on treatments or sponsored topics becomes unlawful advertising when it uses persuasive framing or directs audiences toward specific products, whereas balanced coverage highlighting both benefits and limitations remains legitimate news. Ultimately, commercial intent is evaluated based on tone and audience impact, making careful editorial review essential.
Practical Takeaway for Sponsors
For medical device manufacturers planning PR campaigns or KOL collaborations in Australia, establishing strict internal review processes is essential to ensure media content does not unintentionally trigger TGA advertising penalties.
Understanding a new market often requires both local knowledge and regional experience. With our local offices in Australia & New Zealand and 26+ years of experience across Asia Pacific, Qualtech supports medical device companies in navigating market regulatory requirements and evaluating growth opportunities. Contact us to discuss your plans for the ANZ region.
Reference
TGA, Determining when news is subject to the therapeutic goods advertising rules.